After allogeneic stem cell transplantation (SCT), we evaluated the use of the Wilms' tumor gene (WT1) as a minimal residual disease (MRD) marker in 32 patients (28 chronic myeloid leukemia, three acute lymphoblastic leukemia and one acute myeloid leukemia). All patients expressed BCR-ABL and the kinetics of WT1 were compared with those of BCR-ABL using real-time quantitative PCR. WT1 expression was seen in the peripheral blood (PB) of healthy controls with a median expression level of 7 Â 10 À5 (WT1/ABL ratio). The corresponding values for BCR-ABL-negative and BCR-ABL-positive patient samples were 1 Â 10 À4 and 1.6 Â 10
Summary:
After allogeneic stem cell transplantation (SCT), we evaluated the use of the Wilms' tumor gene (WT1) as a minimal residual disease (MRD) marker in 32 patients (28 chronic myeloid leukemia, three acute lymphoblastic leukemia and one acute myeloid leukemia). All patients expressed BCR-ABL and the kinetics of WT1 were compared with those of BCR-ABL using real-time quantitative PCR. WT1 expression was seen in the peripheral blood (PB) of healthy controls with a median expression level of 7 Â 10 À5 (WT1/ABL ratio). The corresponding values for BCR-ABL-negative and BCR-ABL-positive patient samples were 1 Â 10 À4 and 1.6 Â 10
À4
, respectively. Kinetic studies in individual patients showed that WT1 and BCR-ABL levels usually did not copy each other. In four out of six patients who relapsed, an increase in WT1 from the background level (10
) was observed only at the time of or after relapse, and in two patients increasing WT1 levels were observed before the relapse. In addition, the WT1 values found at the time of relapse were only two logs higher than the background level, indicating a sensitivity of 10 À2 . In conclusion, there is a constitutive low expression of WT1 in normal hematopoietic cells. The sensitivity and ability of WT1 to predict a relapse were poor in this study. Bone Marrow Transplantation (2004) 33, 47-52. doi:10.1038/sj.bmt.1704296 Keywords: WT1; BCR-ABL; minimal residual disease; stem cell transplantation; CML The Philadelphia (Ph) translocation t (9;22) gives rise to the BCR-ABL fusion gene, which is found in more than 90% of patients with chronic myeloid leukemia (CML), 5-40% of patients with acute lymphoblastic leukemia (ALL) and about 1% of patients with acute myeloid leukemia (AML).
1,2 Detection of BCR-ABL mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR) is generally used to assess minimal residual disease (MRD) in patients with Ph-chromosome-positive leukemia. Many studies have shown that quantitative analysis of BCR-ABL levels after allogeneic stem cell transplantation (SCT) has a strong predictive value for relapse. [3] [4] [5] [6] Apart from BCR-ABL detection in CML patients, there is a high heterogeneity with regard to the markers and techniques used to analyze MRD in patients with leukemia. However, in recent years, the use of Wilms' tumor gene (WT1) as a 'panleukemic' marker has been investigated in various studies. [7] [8] [9] WT1 encodes a transcription factor involved in the pathogenesis of Wilms' tumor. Further analyses of this gene have shown that the level of expression is high in most patients with acute leukemia and CML.
10,11
Long-term monitoring of WT1 levels has been used to detect an early relapse and predict the prognosis after chemotherapy or SCT. [12] [13] [14] An association between WT1 expression and relapse, however, has not been found in some studies. [15] [16] [17] In the present study, we wished to evaluate WT1 as an MRD marker by comparing the kinetics of WT1 expression with that of BCR-ABL, which is known to be a 'good' MRD marker. The predictive role of WT1 for relapse was also analyzed.
Patients and methods

Patients
In total, 32 patients (28 CML, three ALL, one AML) receiving allogeneic SCT between October 1998 and February 2002 were included in this study. All of them were positive for the Ph chromosome by FISH analysis at diagnosis and by RT-PCR before and/or after SCT. All patients expressed the p210 transcript. The median age was 38 (range 3-63) years. In all, 12 patients received a nonmyeloablative conditioning regimen with fludarabine, busulfan and antithymocyte globulin (ATG), while 20 received a standard conditioning regimen with cyclophosphamide (120 mg/kg) and TBI. A total of 11 patients received grafts from HLA-identical siblings and 21 from HLA-identical unrelated donors. As a source of stem cells, peripheral blood (PB) and bone marrow (BM) were used in 16 cases each. Graft-versus-host disease prophylaxis consisted mainly of a combination of cyclosporine A and four doses of methotrexate. At the time of SCT, all four patients with acute leukemia were in first complete remission. Of the CML patients, 23 were in the first chronic phase (CP1), three in CP2, one in partial remission and one in the accelerated phase. Details regarding the transplantation procedure and supportive care have been published elsewhere. 18, 19 The Ethics Committee at Karolinska Institutet, Huddinge University Hospital (194/01), approved this study.
Samples
The samples consisted of 5-10 ml of PB or 1-5 ml of BM. A total of 227 samples (185 PB and 42 BM) were analyzed, with a median of seven samples (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] per patient. PB samples from 13 healthy volunteers were used as controls.
RQ-RT-PCR
RNA preparation and reverse transcription. The total RNA was isolated from 1 ml of buffy coat, obtained through centrifugation (400 g for 10 min). The buffy coat was transferred to 6 ml of red cell lysis buffer included in the Qiagen RNA Blood Mini-kit (Qiagen, Hilden, Germany). RNA extraction was then performed according to the instructions of this kit, and RNA was eluted with 30 ml of RNAse-free water.
The cDNA synthesis was performed in a total volume of 50 ml containing 30 ml RNA, 1 Â first-strand buffer (50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl 2 ), 105 mg/ml pdN 6 (Pharmacia Biosciences, Uppsala, Sweden), 1mM of each dNTP (Pharmacia Biosciences), 1mM DTT, 0.48 U/ml RNasin (Promega, Madison, WI, USA) and 4.8 U/ml M-MLV RT (Invitrogen, Paisley, Scotland). After 1.5 h at 371C, the reaction was stopped by heating at 681C for 15 min.
Real-time quantitative-PCR (RQ-PCR)
Quantification was performed on the ABI 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using TaqMan technology. PCR parameters were 2 min, 501C; 10 min, 951C followed by 45 cycles with 15 s, 951C and 1 min, 601C. RQ-PCR reactions were performed in a total volume of 25 ml including 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems, containing dNTPs with dUTP, MgCl 2 , AmpliTaq Gold s DNA Polymerase, AmpErase s UNG, Passive Reference), 2.5 ml of cDNA sample, 300 nM of each primer and 200 nM probe. A plasmid construct containing all four targets (WT1, BCR-ABL, ABL and G6PD (glucose 6-phosphate dehydrogenase)) was obtained by cloning a WT1 fragment (exons 6-7) into the pNC210/G plasmid, kindly provided by Dr NCP Cross, Hammersmith Hospital, London, UK. The serial dilutions of plasmid standards with 4 log steps (10 3 -10 6 for ABL and G6PD and 10 2 -10 5 for BCR-ABL and WT1) were used for each target in each PCR run. The number of target molecules in each unknown sample was calculated automatically using the standard curves from each different target. All samples were run in duplicate and a negative control was included in each run. A threshold value of 0.181871 was used throughout the analyses. ABL and G6PD were used as internal reference genes. Normalized levels of BCR-ABL and WT1 were calculated as the ratios between BCR-ABL and ABL (or G6PD) and between WT1 and ABL (or G6PD). The following primer and probe sequences for BCR-ABL, WT1, ABL and G6PD were used. BCR-ABL-Sense: 
Statistical analysis
The differences between median values were compared using the Mann-Whitney U-test. For the paired blood and BM analysis, the Wilcoxon matched pairs test was used.
Results
Sensitivity of BCR-ABL and WT1 detection
Amplification of serial dilutions of plasmids showed that both BCR-ABL and WT1 could be detected at a level of 10 plasmid copy numbers. In dilution experiments using cells (K562 cells in HL60 cells), a sensitivity of 10 À6 was obtained for BCR-ABL. High correlation coefficiency was obtained for standards in each run (r 2 40.98). The interassay variation was o5% for standards. The interand intra-assay variations for samples were o10%. A good correlation was found between the reference genes ABL and G6PD. The correlation coefficiency was r ¼ 0.71 (Po0.0001) between the BCR-ABL/ABL and BCR-ABL/ G6PD ratios and r ¼ 0.89 (Po0.0001) between the corresponding values of WT1. Since ABL is the more commonly used reference gene, only the results using this gene are shown.
WT1 levels in PB samples
The WT1 expression was detected in the PB samples of all 13 healthy controls. Figure 1 shows the expression levels of WT1 in healthy controls and in patients divided into MRDnegative and MRD-positive samples. The median expression levels in the three groups were 7 Â 10 À5 , 1 Â 10 À4 and 1.6 Â 10
À4
, respectively. WT1 levels in MRD-positive samples were significantly higher than in controls (Po0.05) and MRD-negative samples (P ¼ 0.02). Since both healthy controls and MRD-negative samples showed a median WT1 expression level of about 1 Â 10
, this value was defined as the background expression level.
In 12 samples, no WT1 expression was detected. ABL levels in these samples were significantly (Po0.01) lower than those in WT1-expressing samples, which indicates that the absence of WT1 expression in these samples was probably due to a lower number of cells.
Correlation between BCR-ABL and WT1 expression
The correlation between BCR-ABL and WT1 levels in PB was studied in patients with CML and acute leukemia (AL) separately (Figure 2) . A correlation coefficiency of r ¼ 0.53 (Po0.0001) and r ¼ 0.90 (Po0.0001) was found in CML and AL patients, respectively.
BCR-ABL and WT1 kinetics in individual patients
Patients with relapse. Six patients (four CML, two ALL) relapsed during the time when the samples were analyzed. The kinetics of BCR-ABL and WT1 in these patients are shown in Figure 3 . In patients 1 and 2, there was good correlation between BCR-ABL and WT1 levels. An increase in both markers was detected before the hematological relapse.
In patients 3, 4 and 5, the WT1 levels increased above the background level only at the time or after relapse, while increasing BCR-ABL levels were detected 6, 2 and 2.5 months before relapse, respectively.
In patient 6, MRD was not detected in PB before the relapse. However, BCR-ABL expression was seen in BM at 3 months after SCT. In this patient, the crucial sample before relapse was missing.
In the patients who relapsed, the highest WT1 levels ranged between 1.7 Â 10 À1 and 1.5 Â 10 À3 with a median value of 1 Â 10
À2
. This value exceeds the background expression level by only two logs.
Patients without relapse. The WT1 expression was also detected in all 26 patients who did not relapse. WT1 and BCR-ABL kinetics in six (four CML, one ALL, one AML) representative patients are shown in Figure 4 . Patient 7 had relatively high levels of both BCR-ABL and WT1 without a hematological relapse. In general, WT1 levels above the background level were seen at relatively high BCR-ABL levels (410 À3 ) (patients 8-11), while WT1 returned to background level at lower BCR-ABL levels or MRD negativity (patient 12).
PB vs BM
Of the 42 BM samples available for analysis, 14 were BCR-ABL-negative and 28 were BCR-ABL-positive. The median WT1 levels in the two groups were 1 Â 10 À3 and 1.7 Â 10
À3
(not significant), respectively. These values were about one log of magnitude higher than the corresponding values in PB (see Figure 1 ). Indeed, when the level of WT1 was analyzed in 23 paired PB and BM samples, a one-log difference was observed (Po0.0001). No significant differ- ence in the BCR-ABL expression was found between PB and BM.
Discussion
Relapse remains the major obstacle to successful SCT in patients with leukemia. [20] [21] [22] The use of adoptive immunotherapy, such as discontinuation of immunosuppressive drugs or the administration of donor lymphocyte infusions (DLI), has a strong antileukemic effect, especially if given in the early stages of relapse, when the amount of residual leukemia cells is still small. [23] [24] [25] Therefore, sensitive MRD assays are essential for detection of a threatening relapse and the early start of immunotherapeutic interventions. While current MRD assays are heterogeneous and patient- specific approaches are sometimes needed, the idea of using WT1 as a 'panleukemic' MRD marker is interesting, since only one marker and test could be used for all CML, AML and ALL patients. Although many studies have reported an association between WT1 expression and relapse, some of them have not confirmed these findings. [15] [16] [17] These differences can partly be explained by differences in sensitivities and the use of qualitative vs quantitative analysis.
Regarding sensitivity, the expression of WT1 in the PB of normal healthy controls has previously been reported in only a few studies. 7, 13, 26 Here, we found WT1 expression in all 13 controls with an expression level of 10 À4 (WT1/ABL ratio). This value, although significantly lower than the median value of 1.6 Â 10 À4 in MRD-positive patients, is not low enough to distinguish MRD-positive patients from those in molecular remission. Indeed, a comparison of the range of WT1 levels in MRD-negative and MRDpositive samples in Figure 1 shows that most of the MRD-positive samples are within the same range as the MRD-negative ones. Therefore, only a qualitative analysis of WT1 would have given many false-positive MRD results, and a threshold value of 10 À4 would have resulted in many false negatives. Interestingly, Cillioni et al 26 found a similar expression level in normal PB samples (median 4 Â 10 À4 ) although they detected WT1 expression in only 19 of 33 samples tested.
In some laboratories, molecular relapse in CML patients is defined as a BCR-ABL/ABL ratio 42-5 Â 10
À4
. 25 As shown in Figures 2-4 , this value corresponds to background levels of WT1. An increase in WT1 levels above the background level is seen at BCR-ABL levels of 10 À2 -10 À1 . These values for BCR-ABL, however, are in the range found at cytological or hematological relapse. 27, 28 This was also shown in the kinetic studies in patients who relapsed; an increase in WT1 above the background level was usually found at the time of hematological relapse. Moreover, the highest WT1 values found at the time of relapse were about two logs higher than the background level, which indicates a sensitivity of only 10
À2
. Thus, in this study, the sensitivity and ability of WT1 to predict a relapse was poor.
It has been shown that MRD detection in PB is as sensitive as BM in CML. 29 In 23 paired PB and BM samples we confirmed this finding. However, WT1 expression in BM was one log of magnitude higher than in PB, as reported by others. 12 Therefore, as an MRD marker, WT1 analysis in BM may be less sensitive than PB. Despite this, it has recently been reported in two studies that WT1 analysis in BM is useful for prediction of relapse. 14, 26 One explanation of their findings may be that most of their patients had acute leukemia and that MRD detection in acute leukemia is more sensitively detected in BM than in PB. 30, 31 Also, a decreased background expression level of WT1 was seen in the BM of SCT patients as compared to healthy volunteer donors. 14 In some studies, a high initial expression of WT1 in blasts is required in order to assess MRD during follow-up. 14 Although the initial expression levels of WT1 were not measured in this study due to the absence of diagnosis material, the poor correlation found between WT1 and BCR-ABL levels in most patients suggests that exclusion of some patients might have not changed the results significantly. All patients included in this study expressed BCR-ABL, and since it is not known whether WT1 expression in BCR-ABL-positive and -negative diseases are comparable, the results should be interpreted with some caution.
In conclusion, there is a constitutive low expression of WT1 in normal PB cells. Although there seems to be an upregulation of WT1 at the time of leukemia relapse in BCR-ABL-positive patients, the level and the time of increase are not sufficient to predict a threatening relapse.
